Adverse Reactions to Daily and Intermittent Rifampicin Regimens for Pulmonary Tuberculosis in Hong Kong
This paper reports the nature, incidence, and severity of adverse reactions to regimens of rifampicin and ethambutol given once weekly, twice weekly, or daily and to a standard reserve regimen in a total of 330 Chinese failure patients who completed at least six months' chemotherapy in a therap...
Gespeichert in:
| Veröffentlicht in: | BMJ 1972-03, Vol.1 (5803), p.765-771 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 771 |
|---|---|
| container_issue | 5803 |
| container_start_page | 765 |
| container_title | BMJ |
| container_volume | 1 |
| creator | Aquinas, Sister Mary Allan, W. G. L. Horsfall, P. A. L. Jenkins, P. K. Hung-Yan, Wong Girling, David Tall, Ruth Fox, Wallace |
| description | This paper reports the nature, incidence, and severity of adverse reactions to regimens of rifampicin and ethambutol given once weekly, twice weekly, or daily and to a standard reserve regimen in a total of 330 Chinese failure patients who completed at least six months' chemotherapy in a therapeutic comparison in Hong Kong. The adverse reactions which occurred on the regimens of intermittent rifampicin were termed cutaneous, abdominal, “flu”, and respiratory; in addition, purpura and abnormal liver function tests were encountered. There was an association of adverse reactions with the interval between doses and with the dose size of rifampicin, the highest incidence occurring with once-weekly rifampicin in high dosage. A procedure was developed for managing adverse reactions to intermittent rifampicin. Of 202 patients treated with intermittent rifampicin 60 developed adverse reactions, but in only 7 (3%) was it necessary to terminate the drug, though a further 10 (5%) were changed to daily rifampicin. On daily rifampicin, generalized hypersensitivity, cutaneous reactions, (one with purpura), and impaired liver function were encountered. Adverse reactions on the standard ethionamide, pyrazinamide, and cycloserine regimen were frequent and some were serious. |
| doi_str_mv | 10.1136/bmj.1.5803.765 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1787689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>25418159</jstor_id><sourcerecordid>25418159</sourcerecordid><originalsourceid>FETCH-LOGICAL-b530t-8cedfde35151a12192c77406b4f18b74049d8493bf1608c524d44975c98d4ad83</originalsourceid><addsrcrecordid>eNqFkc1rFDEYh4Modam9ehMCnjzMmHfyORehrtqWFi2lSm8hM5NZs85Mtkmm2P--WXZZ9eQlH_yevHngh9BrICUAFe-bcV1CyRWhpRT8GVoAE6rgitLnaEEIkQUwJl-ikxjX-VpRqWrBjtARq3hdgVyg1Wn3YEO0-MaaNjk_RZw8_mTc8IjN1OGLKdkwupTslPCN6824ca2bMr5yo8107wO-nofRTyY84tu5saGdBx9dxBk799MKX-blFXrRmyHak_1-jL5_-Xy7PC-uvp1dLE-vioZTkgrV2q7vLOXAwUAFddVKyYhoWA-qySdWd4rVtOlBENXyinWM1ZK3teqY6RQ9Rh92czdzM9quzdrBDHoT3Jj9tDdO_5tM7qde-QcNUkmh6jzg7X5A8PezjUmv_Rym7JwRKSpRUSozVe6oNvgYg-0PPwDR22p0rkaD3lajczX5wZu_vQ74vog_-TomHw5xxRko4FutYpe7mOzvQ27CLy0klVx__bHU13fk7vKjAM0y_27Hbz3-4_YEmQywhw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776262337</pqid></control><display><type>article</type><title>Adverse Reactions to Daily and Intermittent Rifampicin Regimens for Pulmonary Tuberculosis in Hong Kong</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>PubMed Central</source><creator>Aquinas, Sister Mary ; Allan, W. G. L. ; Horsfall, P. A. L. ; Jenkins, P. K. ; Hung-Yan, Wong ; Girling, David ; Tall, Ruth ; Fox, Wallace</creator><creatorcontrib>Aquinas, Sister Mary ; Allan, W. G. L. ; Horsfall, P. A. L. ; Jenkins, P. K. ; Hung-Yan, Wong ; Girling, David ; Tall, Ruth ; Fox, Wallace</creatorcontrib><description>This paper reports the nature, incidence, and severity of adverse reactions to regimens of rifampicin and ethambutol given once weekly, twice weekly, or daily and to a standard reserve regimen in a total of 330 Chinese failure patients who completed at least six months' chemotherapy in a therapeutic comparison in Hong Kong. The adverse reactions which occurred on the regimens of intermittent rifampicin were termed cutaneous, abdominal, “flu”, and respiratory; in addition, purpura and abnormal liver function tests were encountered. There was an association of adverse reactions with the interval between doses and with the dose size of rifampicin, the highest incidence occurring with once-weekly rifampicin in high dosage. A procedure was developed for managing adverse reactions to intermittent rifampicin. Of 202 patients treated with intermittent rifampicin 60 developed adverse reactions, but in only 7 (3%) was it necessary to terminate the drug, though a further 10 (5%) were changed to daily rifampicin. On daily rifampicin, generalized hypersensitivity, cutaneous reactions, (one with purpura), and impaired liver function were encountered. Adverse reactions on the standard ethionamide, pyrazinamide, and cycloserine regimen were frequent and some were serious.</description><identifier>ISSN: 0007-1447</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.1.5803.765</identifier><identifier>PMID: 4259217</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Adverse drug reactions ; Alanine Transaminase - blood ; Antitubercular Agents - adverse effects ; Antituberculars ; Bone Diseases - chemically induced ; Chemical and Drug Induced Liver Injury ; Chemotherapy ; Colic - chemically induced ; Dosage ; Dosage forms ; Drug Eruptions - etiology ; Dyspnea - chemically induced ; Ethambutol - administration & dosage ; Ethambutol - adverse effects ; Exanthema ; Fever - chemically induced ; Hong Kong ; Humans ; Hypersensitive response ; Jaundice ; Jaundice - chemically induced ; Papers and Originals ; Purpura ; Purpura - chemically induced ; Rifampin - administration & dosage ; Rifampin - adverse effects ; Time Factors ; Tuberculosis ; Tuberculosis, Pulmonary - drug therapy</subject><ispartof>BMJ, 1972-03, Vol.1 (5803), p.765-771</ispartof><rights>Copyright 1972 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Mar 25, 1972</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b530t-8cedfde35151a12192c77406b4f18b74049d8493bf1608c524d44975c98d4ad83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/25418159$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/25418159$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,723,776,780,799,881,27903,27904,53770,53772,57996,58229</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4259217$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aquinas, Sister Mary</creatorcontrib><creatorcontrib>Allan, W. G. L.</creatorcontrib><creatorcontrib>Horsfall, P. A. L.</creatorcontrib><creatorcontrib>Jenkins, P. K.</creatorcontrib><creatorcontrib>Hung-Yan, Wong</creatorcontrib><creatorcontrib>Girling, David</creatorcontrib><creatorcontrib>Tall, Ruth</creatorcontrib><creatorcontrib>Fox, Wallace</creatorcontrib><title>Adverse Reactions to Daily and Intermittent Rifampicin Regimens for Pulmonary Tuberculosis in Hong Kong</title><title>BMJ</title><addtitle>Br Med J</addtitle><description>This paper reports the nature, incidence, and severity of adverse reactions to regimens of rifampicin and ethambutol given once weekly, twice weekly, or daily and to a standard reserve regimen in a total of 330 Chinese failure patients who completed at least six months' chemotherapy in a therapeutic comparison in Hong Kong. The adverse reactions which occurred on the regimens of intermittent rifampicin were termed cutaneous, abdominal, “flu”, and respiratory; in addition, purpura and abnormal liver function tests were encountered. There was an association of adverse reactions with the interval between doses and with the dose size of rifampicin, the highest incidence occurring with once-weekly rifampicin in high dosage. A procedure was developed for managing adverse reactions to intermittent rifampicin. Of 202 patients treated with intermittent rifampicin 60 developed adverse reactions, but in only 7 (3%) was it necessary to terminate the drug, though a further 10 (5%) were changed to daily rifampicin. On daily rifampicin, generalized hypersensitivity, cutaneous reactions, (one with purpura), and impaired liver function were encountered. Adverse reactions on the standard ethionamide, pyrazinamide, and cycloserine regimen were frequent and some were serious.</description><subject>Adverse drug reactions</subject><subject>Alanine Transaminase - blood</subject><subject>Antitubercular Agents - adverse effects</subject><subject>Antituberculars</subject><subject>Bone Diseases - chemically induced</subject><subject>Chemical and Drug Induced Liver Injury</subject><subject>Chemotherapy</subject><subject>Colic - chemically induced</subject><subject>Dosage</subject><subject>Dosage forms</subject><subject>Drug Eruptions - etiology</subject><subject>Dyspnea - chemically induced</subject><subject>Ethambutol - administration & dosage</subject><subject>Ethambutol - adverse effects</subject><subject>Exanthema</subject><subject>Fever - chemically induced</subject><subject>Hong Kong</subject><subject>Humans</subject><subject>Hypersensitive response</subject><subject>Jaundice</subject><subject>Jaundice - chemically induced</subject><subject>Papers and Originals</subject><subject>Purpura</subject><subject>Purpura - chemically induced</subject><subject>Rifampin - administration & dosage</subject><subject>Rifampin - adverse effects</subject><subject>Time Factors</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Pulmonary - drug therapy</subject><issn>0007-1447</issn><issn>0959-8138</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1972</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkc1rFDEYh4Modam9ehMCnjzMmHfyORehrtqWFi2lSm8hM5NZs85Mtkmm2P--WXZZ9eQlH_yevHngh9BrICUAFe-bcV1CyRWhpRT8GVoAE6rgitLnaEEIkQUwJl-ikxjX-VpRqWrBjtARq3hdgVyg1Wn3YEO0-MaaNjk_RZw8_mTc8IjN1OGLKdkwupTslPCN6824ca2bMr5yo8107wO-nofRTyY84tu5saGdBx9dxBk799MKX-blFXrRmyHak_1-jL5_-Xy7PC-uvp1dLE-vioZTkgrV2q7vLOXAwUAFddVKyYhoWA-qySdWd4rVtOlBENXyinWM1ZK3teqY6RQ9Rh92czdzM9quzdrBDHoT3Jj9tDdO_5tM7qde-QcNUkmh6jzg7X5A8PezjUmv_Rym7JwRKSpRUSozVe6oNvgYg-0PPwDR22p0rkaD3lajczX5wZu_vQ74vog_-TomHw5xxRko4FutYpe7mOzvQ27CLy0klVx__bHU13fk7vKjAM0y_27Hbz3-4_YEmQywhw</recordid><startdate>19720325</startdate><enddate>19720325</enddate><creator>Aquinas, Sister Mary</creator><creator>Allan, W. G. L.</creator><creator>Horsfall, P. A. L.</creator><creator>Jenkins, P. K.</creator><creator>Hung-Yan, Wong</creator><creator>Girling, David</creator><creator>Tall, Ruth</creator><creator>Fox, Wallace</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>19720325</creationdate><title>Adverse Reactions to Daily and Intermittent Rifampicin Regimens for Pulmonary Tuberculosis in Hong Kong</title><author>Aquinas, Sister Mary ; Allan, W. G. L. ; Horsfall, P. A. L. ; Jenkins, P. K. ; Hung-Yan, Wong ; Girling, David ; Tall, Ruth ; Fox, Wallace</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b530t-8cedfde35151a12192c77406b4f18b74049d8493bf1608c524d44975c98d4ad83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1972</creationdate><topic>Adverse drug reactions</topic><topic>Alanine Transaminase - blood</topic><topic>Antitubercular Agents - adverse effects</topic><topic>Antituberculars</topic><topic>Bone Diseases - chemically induced</topic><topic>Chemical and Drug Induced Liver Injury</topic><topic>Chemotherapy</topic><topic>Colic - chemically induced</topic><topic>Dosage</topic><topic>Dosage forms</topic><topic>Drug Eruptions - etiology</topic><topic>Dyspnea - chemically induced</topic><topic>Ethambutol - administration & dosage</topic><topic>Ethambutol - adverse effects</topic><topic>Exanthema</topic><topic>Fever - chemically induced</topic><topic>Hong Kong</topic><topic>Humans</topic><topic>Hypersensitive response</topic><topic>Jaundice</topic><topic>Jaundice - chemically induced</topic><topic>Papers and Originals</topic><topic>Purpura</topic><topic>Purpura - chemically induced</topic><topic>Rifampin - administration & dosage</topic><topic>Rifampin - adverse effects</topic><topic>Time Factors</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Pulmonary - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aquinas, Sister Mary</creatorcontrib><creatorcontrib>Allan, W. G. L.</creatorcontrib><creatorcontrib>Horsfall, P. A. L.</creatorcontrib><creatorcontrib>Jenkins, P. K.</creatorcontrib><creatorcontrib>Hung-Yan, Wong</creatorcontrib><creatorcontrib>Girling, David</creatorcontrib><creatorcontrib>Tall, Ruth</creatorcontrib><creatorcontrib>Fox, Wallace</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aquinas, Sister Mary</au><au>Allan, W. G. L.</au><au>Horsfall, P. A. L.</au><au>Jenkins, P. K.</au><au>Hung-Yan, Wong</au><au>Girling, David</au><au>Tall, Ruth</au><au>Fox, Wallace</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse Reactions to Daily and Intermittent Rifampicin Regimens for Pulmonary Tuberculosis in Hong Kong</atitle><jtitle>BMJ</jtitle><addtitle>Br Med J</addtitle><date>1972-03-25</date><risdate>1972</risdate><volume>1</volume><issue>5803</issue><spage>765</spage><epage>771</epage><pages>765-771</pages><issn>0007-1447</issn><issn>0959-8138</issn><eissn>1468-5833</eissn><abstract>This paper reports the nature, incidence, and severity of adverse reactions to regimens of rifampicin and ethambutol given once weekly, twice weekly, or daily and to a standard reserve regimen in a total of 330 Chinese failure patients who completed at least six months' chemotherapy in a therapeutic comparison in Hong Kong. The adverse reactions which occurred on the regimens of intermittent rifampicin were termed cutaneous, abdominal, “flu”, and respiratory; in addition, purpura and abnormal liver function tests were encountered. There was an association of adverse reactions with the interval between doses and with the dose size of rifampicin, the highest incidence occurring with once-weekly rifampicin in high dosage. A procedure was developed for managing adverse reactions to intermittent rifampicin. Of 202 patients treated with intermittent rifampicin 60 developed adverse reactions, but in only 7 (3%) was it necessary to terminate the drug, though a further 10 (5%) were changed to daily rifampicin. On daily rifampicin, generalized hypersensitivity, cutaneous reactions, (one with purpura), and impaired liver function were encountered. Adverse reactions on the standard ethionamide, pyrazinamide, and cycloserine regimen were frequent and some were serious.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>4259217</pmid><doi>10.1136/bmj.1.5803.765</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1447 |
| ispartof | BMJ, 1972-03, Vol.1 (5803), p.765-771 |
| issn | 0007-1447 0959-8138 1468-5833 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1787689 |
| source | Jstor Complete Legacy; MEDLINE; PubMed Central |
| subjects | Adverse drug reactions Alanine Transaminase - blood Antitubercular Agents - adverse effects Antituberculars Bone Diseases - chemically induced Chemical and Drug Induced Liver Injury Chemotherapy Colic - chemically induced Dosage Dosage forms Drug Eruptions - etiology Dyspnea - chemically induced Ethambutol - administration & dosage Ethambutol - adverse effects Exanthema Fever - chemically induced Hong Kong Humans Hypersensitive response Jaundice Jaundice - chemically induced Papers and Originals Purpura Purpura - chemically induced Rifampin - administration & dosage Rifampin - adverse effects Time Factors Tuberculosis Tuberculosis, Pulmonary - drug therapy |
| title | Adverse Reactions to Daily and Intermittent Rifampicin Regimens for Pulmonary Tuberculosis in Hong Kong |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T18%3A52%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20Reactions%20to%20Daily%20and%20Intermittent%20Rifampicin%20Regimens%20for%20Pulmonary%20Tuberculosis%20in%20Hong%20Kong&rft.jtitle=BMJ&rft.au=Aquinas,%20Sister%20Mary&rft.date=1972-03-25&rft.volume=1&rft.issue=5803&rft.spage=765&rft.epage=771&rft.pages=765-771&rft.issn=0007-1447&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.1.5803.765&rft_dat=%3Cjstor_pubme%3E25418159%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776262337&rft_id=info:pmid/4259217&rft_jstor_id=25418159&rfr_iscdi=true |